GLP-1s
The road to pharmaceutical perdition?
Originally marketed as a medication to help manage type 2 diabetes, GLP-1s are being heralded as a miracle weight loss treatment. Indeed, many people have lost a lot of weight.
Everywhere you see celebrities and people you know who've noticeably slimmed down. Every day you see some new claim about the wonders of GLP-1s.
But amidst the clamor there are voices of concern. Nonetheless, there are people who claim GLP-1s saved their lives. They certainly made them thinner. So this seems like the perfect topic for an AI Q&A. Grab your favorite snack and join me as we go down the GLP-1 rabbit hole with AI.
Question
Let's start with a brief AI explanation of what GLP-1s are.
AI answer
GLP-1s are a class of medications—including well-known brands like Ozempic and Wegovy—that mimic a naturally occurring hormone your body releases after eating. They work by signaling your pancreas to produce insulin when blood sugar is high, while also slowing down digestion so food stays in your stomach longer. This dual action not only helps manage type 2 diabetes but also sends powerful signals to your brain that you are full, significantly reducing appetite and cravings, which is why they have become highly effective and popular tools for weight management.
Question
Beyond weight loss, what claims are daily being made about other benefits of GLP-1s?
AI answer
Beyond their primary roles in managing blood sugar and driving weight loss, GLP-1 receptor agonists are increasingly recognized for a wide array of secondary health benefits. Because these medications influence systemic inflammation and act on receptors throughout the body and brain, researchers are uncovering significant impacts across several different medical fields.
Here is a breakdown of the latest claims and ongoing research regarding the broader benefits of GLP-1s:
Cardiovascular Health: GLP-1s have been shown to significantly reduce the risk of major adverse cardiovascular events—such as heart attacks, strokes, and cardiovascular-related death. They are also proving effective at improving outcomes and reducing hospitalizations for patients with certain types of heart failure (Gonzalez-Rellan, n.d.).
Kidney Protection: These medications appear to slow the progression of chronic kidney disease. Clinical trials indicate they help preserve kidney function, reduce excess protein in the urine, and lower the overall risk of major adverse kidney events in diabetic patients (Matuszewski, n.d.).
Addiction and Substance Use: Because GLP-1 receptors are present in the brain's reward centers, these drugs can mute the dopamine response associated with addictive behaviors. Current studies and patient reports show that GLP-1s can significantly reduce the craving and consumption of alcohol, nicotine, opioids, and other substances (Völker, n.d.).
Mental Health and Cognitive Decline: Big-data analyses of patient records suggest that individuals taking GLP-1s experience lower rates of anxiety, depression, and suicidal ideation compared to those on other medications. Additionally, their ability to reduce neuroinflammation has sparked clinical trials investigating their potential to protect against neurodegenerative conditions like Alzheimer's and Parkinson's disease (Matuszewski, n.d.).
Liver Disease and Sleep Apnea: GLP-1s are highly effective at reducing fat buildup in the liver, making them a primary treatment target for fatty liver disease. Furthermore, the resulting metabolic improvements have been linked to significantly reduced severity of obstructive sleep apnea (Gonzalez-Rellan, n.d.).
Cancer Prevention and Adjunct Treatment: One of the most recent and promising areas of research involves oncology. Large-scale observational studies have associated GLP-1 use with a significantly lower incidence of several obesity-related cancers, including breast, endometrial, and ovarian cancers (Dai, n.d.; McDonald, n.d.). Beyond prevention, early laboratory research suggests that GLP-1s might actively inhibit tumor cell growth and reduce local inflammation, leading scientists to explore their use as a supportive treatment alongside standard cancer therapies for solid tumors (Lucente, n.d.).
Question
No doubt many people appear to have benefited from GLP-1s. But concerns are being raised as well. We've seen images of very frail looking people who later publicly denounced GLP-1s.
One prominent example is Sharon Osbourne, an English and American television personality, businesswoman and author who was married to heavy metal singer Ozzy Osbourne. She cited many adverse reactions, such as nausea, and ultimately decided taking GLP-1s wasn't worth it. She just didn't feel or look healthy.
AI answer
Feeling like the weight loss just comes from being too sick to eat is exactly how many people experience these medications when their bodies don't tolerate them. While the intended mechanism is to gently slow digestion and signal the brain's fullness centers, for a significant number of people, that slowed digestion simply results in constant gastrointestinal distress. In those cases, you aren't losing weight because the drug is optimizing your metabolism; you're losing weight because you're simply too sick to consume food.
You also pointed out a very real and growing medical concern: the extreme frailty seen in some public figures. As the initial wave of excitement around GLP-1s has settled, the medical community is having to manage several serious downsides:
Severe Muscle Loss: When people lose weight rapidly on GLP-1s, they aren't just losing fat—up to 40% of the weight lost can be lean muscle mass. If someone's appetite is so suppressed that they aren't eating enough protein or strength training, they can become physically frail. This leads to the gaunt appearance you noted and can significantly weaken the body overall.
Gastrointestinal Paralysis: The severe side effects you dealt with are the most common reason people quit. In rare but serious cases, slowing down the digestive tract can lead to gastroparesis (stomach paralysis) or bowel obstructions, which can land people in the hospital.
The Rebound Effect: These medications are designed to be taken long-term. Clinical trials show that when people stop taking them, the intense hunger signals return quickly. This often leads to a rapid regain of the weight, and unfortunately, people tend to regain fat rather than the muscle they lost.
Organ Stress: There is a well-documented increased risk of developing gallstones or acute inflammation of the pancreas (pancreatitis), both of which can require emergency surgery.
These medications are undoubtedly powerful tools for those who tolerate them well and have serious metabolic conditions, but they are far from a universal or harmless fix.
Question
In the past, pharmaceuticals have been promoted with great fanfare—only to be restricted or withdrawn, some following major class action lawsuits. Create a list of examples since the 1960s. Give a brief explanation of what happened.
AI Answer
Baycol (cerivastatin): Severe rhabdomyolysis (muscle breakdown) leading to kidney failure and deaths (including when combined with certain other drugs).
Belviq (lorcaserin): Increased occurrence of cancer (e.g., pancreatic, colorectal, lung) shown in long-term clinical trials; FDA-requested market withdrawal in 2020.
Bextra (valdecoxib): Serious cardiovascular events (heart attack, stroke, death) plus severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis); withdrawn in 2005.
DES (diethylstilbestrol): Caused vaginal/cervical cancer, reproductive tract abnormalities, and other issues in daughters of women who took it during pregnancy; use in pregnancy was banned.
Fen-phen (fenfluramine + phentermine combination): Cardiotoxicity, including valvular heart disease and primary pulmonary hypertension; fenfluramine component (and its chemical cousin, dexfenfluramine) withdrawn in 1997. The phentermine component remains a commonly prescribed, FDA-approved weight loss medication today.
Meridia (sibutramine): Increased risk of heart attack and stroke (confirmed in long-term cardiovascular outcomes trial); withdrawn worldwide around 2010.
OxyContin (oxycodone): Aggressive marketing downplayed addiction risk; its extended-release formulation was highly abusable, fueling widespread dependence, overdoses, and the opioid crisis. The original formulation was officially discontinued in 2010 and replaced with an "abuse-deterrent" formulation designed to be harder to crush, chew, or dissolve for snorting or injecting. The medication itself was never withdrawn.
Propulsid (cisapride): Serious heart rhythm problems (QT prolongation and torsades de pointes) leading to deaths. While effectively withdrawn from the general retail market in 2000, it is still available in the U.S. for extremely rare, treatment-resistant digestive conditions. It is dispensed strictly through a highly monitored investigational limited-access program.
Rezulin (troglitazone): Severe liver toxicity and liver failure (dozens of deaths reported); withdrawn in 2000.
Seldane (terfenadine): Life-threatening cardiac arrhythmias (torsades de pointes), especially when combined with certain drugs or foods; withdrawn in 1998.
Thalidomide: Severe birth defects (e.g., phocomelia/limb malformations) in babies when taken by pregnant women; major global withdrawal in the early 1960s (later reintroduced under strict controls for other uses).
Vioxx (rofecoxib): Increased risk of heart attacks and strokes; voluntarily withdrawn by Merck in 2004.
Zantac (ranitidine): Contamination with NDMA (a probable human carcinogen), with levels rising over time or with heat/storage; all contaminated products withdrawn from the market in 2020. However, you will still see "Zantac" on pharmacy shelves today. The manufacturer preserved the brand name by switching the active ingredient to famotidine (rebranding it as "Zantac 360"), which does not have the NDMA degradation issue.
My response
I tried a GLP-1 myself. After two weeks of diarrhea, headaches, and nausea I gave up. And I was taking the smallest dose.
Looking back, it makes sense that if you feel miserable all the time you won't want to eat and will lose weight. But, for me at least, it was like scratching an itch with sandpaper. Just too much discomfort and hassle.
Considering all the negatives, there still appear to be notable positives.
That said, the proliferation of GLP-1 based weight loss medical clinics, including online services, suggests caution. Remember: Doctors unhesitatingly prescribed Thalidomide, Fen-phen, and OxyContin—which was good medical practice, until it wasn't.
Anything that significantly affects your life requires serious research and reflection. That is your responsibility.